Component: (Network and Table)
Network
00100 - Statement - Consolidated Balance Sheets
(http://www.onconova.com/role/StatementConsolidatedBalanceSheets)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001130598 (http://www.sec.gov/CIK)
Consolidated Balance SheetsPeriod [Axis]
2016-12-31
2015-12-31
Consolidated Balance Sheets
 
 
Assets
 
 
Current assets:
 
 
Cash and cash equivalents
21,400,000  
19,799,000  
Receivables
31,000  
1,504,000  
Prepaid expenses and other current assets
1,588,000  
1,832,000  
Restricted cash
50,000  
50,000  
Total current assets
23,069,000  
 
23,185,000  
 
Property and equipment, net
152,000  
248,000  
Other non-current assets
12,000  
12,000  
Total assets
23,233,000  
 
23,445,000  
 
Liabilities and stockholders' equity
 
 
Current liabilities:
 
 
Accounts payable
5,323,000  
3,421,000  
Accrued expenses and other current liabilities
4,382,000  
3,729,000  
Deferred revenue
455,000  
455,000  
Total current liabilities
10,160,000  
 
7,605,000  
 
Warrant liability
3,401,000  
 
Deferred revenue, non-current
4,545,000  
5,000,000  
Total liabilities
18,106,000  
 
12,605,000  
 
Commitments and contingencies
xsi:nil  
xsi:nil  
Stockholders' equity:
 
 
Preferred stock, $0.01 par value, 5,000,000 authorized at December 31, 2016 and 2015, none issued and outstanding at December 31, 2016 and 2015
xsi:nil  
xsi:nil  
Common stock, $0.01 par value, 25,000,000 and 75,000,000 authorized at December 31, 2016 and 2015, 6,759,895 and 2,546,419 shares issued and outstanding at December 31, 2016 and 2015
68,000  
25,000  
Additional paid in capital
342,484,000  
328,564,000  
Accumulated other comprehensive income
(31,000) 
(22,000) 
Accumulated deficit
(338,224,000) 
(318,557,000) 
Total Onconova Therapeutics, Inc. stockholders' equity
4,297,000  
 
10,010,000  
 
Non-controlling interest
830,000  
830,000  
Total stockholders' equity
5,127,000  
 
10,840,000  
 
Total liabilities and stockholders' equity
23,233,000  
 
23,445,000